<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495168</url>
  </required_header>
  <id_info>
    <org_study_id>ACT-2015-075-0AA</org_study_id>
    <nct_id>NCT02495168</nct_id>
  </id_info>
  <brief_title>Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants</brief_title>
  <official_title>A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter, Multinational Study to Compare the Therapeutic Equivalence of a Budesonide 80 μg/Formoterol Fumarate Dihydrate 4.5 μg Inhalation Aerosol (Manufactured by Catalent for Watson Laboratories Inc.) to Symbicort® (Budesonide 80 μg/Formoterol Fumarate Dihydrate 4.5 μg Inhalation Aerosol) (Manufactured by AstraZeneca) in Adolescent and Adult Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has a randomized multiple-dose, placebo-controlled, parallel group design&#xD;
      consisting of a 2-week open placebo Run-in Period followed by a 6-week Treatment Period with&#xD;
      placebo, test product (budesonide 80 microgram [μg]/formoterol fumarate dihydrate 4.5 μg), or&#xD;
      reference product (Symbicort® inhalation aerosol).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pivotal trial that will examine the therapeutic equivalence of a new generic&#xD;
      fixed-dose combination product containing budesonide 80 μg/formoterol fumarate dihydrate 4.5&#xD;
      μg and reference listed drug (RLD) Symbicort® inhalation aerosol in adult participants with&#xD;
      chronic but stable asthma as defined in National Asthma Education and Prevention Program&#xD;
      Expert Panel Report 3 (NAEPP 3) guidelines. To ensure adequate study sensitivity, the test&#xD;
      and reference products should both be statistically superior to placebo (p&lt;0.05) with regard&#xD;
      to the bioequivalent study primary endpoints. Participants will be provided a generic placebo&#xD;
      pressurized metered-dose inhaler (pMDI) device for use during the 2-week Run-in Period for&#xD;
      device training.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2017</start_date>
  <completion_date type="Actual">May 31, 2018</completion_date>
  <primary_completion_date type="Actual">May 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Equivalence Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV1 Area Under Curve [AUC0-12]) on the First Day of Treatment</measure>
    <time_frame>0 to 12 hours on Day 1</time_frame>
    <description>FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Baseline-adjusted area under the serial FEV1-time curve was calculated from Time 0 to 12 hours on the first day of the Treatment Period (Day 1). FEV1 AUC0-12 was calculated from baseline-adjusted values using the linear trapezoidal method. The calculation assumed that at time of dosing (Time 0) the baseline adjusted FEV1 was also 0. The calculation proceeded over all available post-dose FEV1 assessments on Day 1 (including unscheduled time points, if any) using actual elapsed time from dosing. FEV1 baseline defined as the average of predose FEV1 values obtained on Day 1. If some of these values were missing, the average was calculated using the available values, however, a minimum of 2 predose FEV1 values were required; participants who had only 1 or no predose FEV1 measurements on Day 1 would have their FEV1 baseline missing, and the participant was to be excluded from analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superiority Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV AUC0-12) on the First Day of Treatment</measure>
    <time_frame>0 to 12 hours on Day 1</time_frame>
    <description>FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Baseline-adjusted area under the serial FEV1-time curve was calculated from Time 0 to 12 hours on the first day of the Treatment Period (Day 1). FEV1 AUC0-12 was calculated from baseline-adjusted values using the linear trapezoidal method. The calculation assumed that at time of dosing (Time 0) the baseline adjusted FEV1 was also 0. The calculation proceeded over all available post-dose FEV1 assessments on Day 1 (including unscheduled time points, if any) using actual elapsed time from dosing. FEV1 baseline defined as the average of predose FEV1 values obtained on Day 1. If some of these values were missing, the average was calculated using the available values, however, a minimum of 2 predose FEV1 values were required; participants who had only 1 or no predose FEV1 measurements on Day 1 would have their FEV1 baseline missing, and the participant was to be excluded from analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Equivalence Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment</measure>
    <time_frame>Day 1 up to Day 50</time_frame>
    <description>FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42. If a participant had no predose assessment on Day 42, the average of all available predose assessments on the last day (for example, Early Termination visit [up to Day 50]) when at least 1 predose FEV1 assessments was available was imputed, if the participant discontinued due to lack of efficacy, otherwise there was no imputation. Baseline was defined as the average of at least 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: [FEV1 at end of treatment] - [Baseline FEV1].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superiority Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment</measure>
    <time_frame>Day 1 up to Day 50</time_frame>
    <description>FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42. If a participant had no predose assessment on Day 42, the average of all available predose assessments on the last day (for example, Early Termination visit [up to Day 50]) when at least 1 predose FEV1 assessments was available was imputed, if the participant discontinued due to lack of efficacy, otherwise there was no imputation. Baseline was defined as the average of at least 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: [FEV1 at end of treatment] - [Baseline FEV1].</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1714</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Generic Budesonide/Formoterol Fumarate Dihydrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort (Budesonide/Formoterol Fumarate Dihydrate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic Budesonide/Formoterol Fumarate Dihydrate</intervention_name>
    <description>Oral inhalation, generic formulation of the brand-name product.</description>
    <arm_group_label>Generic Budesonide/Formoterol Fumarate Dihydrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)</intervention_name>
    <description>Oral inhalation, brand-name product.</description>
    <arm_group_label>Symbicort (Budesonide/Formoterol Fumarate Dihydrate)</arm_group_label>
    <other_name>Symbicort Turbohaler®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral inhalation, no active ingredient.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Adolescent and adult male or female participants (≥12 and ≤75 years of age).&#xD;
&#xD;
          2. Female participants must not be lactating or pregnant at Screening, as documented by a&#xD;
             negative serum pregnancy test with a minimum sensitivity of 25 international&#xD;
             unit/liter (IU/L) or equivalent units of beta-human chorionic gonadotropin (β-hCG) at&#xD;
             Screening.&#xD;
&#xD;
          3. Women of childbearing potential (WOCBP) and female partners (WOCBP) of male&#xD;
             participants participating in the study, must commit to consistent and correct use of&#xD;
             an acceptable method of birth control (at the Investigator's discretion) throughout&#xD;
             the study and for 30 days after study drug discontinuation.&#xD;
&#xD;
          4. Male participants and male partners of female participants (WOCBP) must commit to&#xD;
             consistent and correct use of an acceptable method of birth control (at the&#xD;
             Investigator's discretion) throughout the study and for 30 days after the study drug&#xD;
             discontinuation.&#xD;
&#xD;
          5. Diagnosed with asthma as defined by the NAEPP 3 at least 6 months prior to Screening.&#xD;
             If the participant is new to the study site, the Investigator must confirm the&#xD;
             participant's asthma diagnosis. Acceptable means include either medical records or&#xD;
             pharmacy records.&#xD;
&#xD;
          6. Moderate to severe asthma with a pre-bronchodilator forced expiratory volume in 1&#xD;
             second (FEV1) of ≥45% and ≤85% of the predicted normal value during measured at least&#xD;
             6 hours after short-acting β agonist (SABA) and at least 24 hours after the last dose&#xD;
             of long-acting β agonist (LABA) at Screening and prior to randomization on Day 1.&#xD;
&#xD;
          7. Currently non-smoking, negative for urine cotinine at Screening, having not used&#xD;
             tobacco products (that is, cigarettes, cigars, pipe tobacco, and electronic&#xD;
             cigarettes) within the past year, and had ≤10 pack-years of historical use.&#xD;
&#xD;
          8. Body mass index (BMI) between 18 to 40 (inclusive) for participants ≥18 years old. For&#xD;
             adolescent participants 12 to 17 years old, BMI between 15 to 40 inclusive (in&#xD;
             accordance with the BMI range typical for the age).&#xD;
&#xD;
          9. ≥15% and ≥0.20 L reversibility of FEV1 within 30 minutes following 360 μg (4 puffs) of&#xD;
             albuterol (400 μg salbutamol) inhalation (pMDI). If the participant achieves &lt;15%, but&#xD;
             ≥10% reversibility at the Screening, the site may instruct the participant to hold&#xD;
             LABA and/or inhaled corticosteroids (ICS) and return up to 7 days later for a repeat&#xD;
             test. Only 1 repeat of the Screening spirometry test (to retest reversibility) is&#xD;
             allowed.&#xD;
&#xD;
         10. Able to perform valid and reproducible spirometry results per American Thoracic&#xD;
             Society/European Respiratory Society (ATS/ERS) standards at Screening.&#xD;
&#xD;
         11. Able to inhale study drug properly.&#xD;
&#xD;
         12. Willing to discontinue asthma medications (ICS and LABAs) during the Run-in Period and&#xD;
             for the remainder of the study.&#xD;
&#xD;
         13. Able to replace current regularly scheduled SABAs with albuterol/salbutamol inhaler&#xD;
             for use only on as needed basis for the duration of the study (participants should be&#xD;
             able to withhold all inhaled SABAs for at least 6 hours prior to lung function&#xD;
             assessments on study visits).&#xD;
&#xD;
         14. Able to continue the following medications without a significant adjustment of dosage,&#xD;
             formulation, dosing interval for the duration of the study, and judged able by the&#xD;
             Investigator to withhold them for the specified minimum time intervals prior to each&#xD;
             clinic visit, if applicable:&#xD;
&#xD;
               1. Short-acting forms of theophylline: 12 hours.&#xD;
&#xD;
               2. Twice-a-day controlled-release forms of theophylline: 24 hours.&#xD;
&#xD;
               3. Once-a-day controlled-release forms of theophylline: 36 hours.&#xD;
&#xD;
         15. Able to discontinue the following medications for the specified minimum time intervals&#xD;
             prior to the Run-in Period and for the remainder of the study, if applicable:&#xD;
&#xD;
               1. Oral corticosteroids for 30 days.&#xD;
&#xD;
               2. Parenteral corticosteroids for 30 days.&#xD;
&#xD;
               3. Oral (not inhaled) SABAs for 24 hours.&#xD;
&#xD;
         16. Clinical laboratory tests (clinical chemistry, hematology, and urinalysis) and 12-lead&#xD;
             electrocardiogram (ECG) conducted at Screening within normal limits or abnormal but&#xD;
             not clinically significant to the Investigator. The QTc should be calculated using&#xD;
             Bazett's formula.&#xD;
&#xD;
         17. Willing to give written informed consent/assent, and willing and able to follow the&#xD;
             study rules and procedures.&#xD;
&#xD;
         18. Stable on chronic asthma treatment regimen for at least 4 weeks prior to enrollment.&#xD;
&#xD;
         19. Ability to perform forced expiratory assessments according to ATS standards.&#xD;
&#xD;
        Randomization eligibility criteria:&#xD;
&#xD;
          1. Baseline pre-bronchodilator FEV1 should be ≥45% and ≤85% of predicted normal value and&#xD;
             not vary by more than ±20% from Screening FEV1 value.&#xD;
&#xD;
          2. Compliance during the Run-in Period of at least 75% based on electronic Diary entries&#xD;
             is required for a participant to qualify for randomization. Compliance with the run-in&#xD;
             placebo treatment must be between 75% and 125%.&#xD;
&#xD;
          3. Documented total asthma symptom score of ≥1 for at least 2 days during the Run-in&#xD;
             Period.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Life-threatening asthma, defined as a history of asthma episode(s) requiring&#xD;
             intubation, and/or associated with hypercapnea, respiratory arrest or hypoxic&#xD;
             seizures, asthma-related syncopal episode(s), or hospitalizations within the past year&#xD;
             or during the Run-in Period.&#xD;
&#xD;
          2. Exercise-induced asthma as the only asthma-related diagnosis.&#xD;
&#xD;
          3. Evidence or history of clinically significant disease or abnormality including&#xD;
             congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery&#xD;
             disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or&#xD;
             current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal,&#xD;
             or other diseases that in the opinion of the Investigator would put the participant at&#xD;
             risk through study participation or would affect the study analyses if the disease&#xD;
             exacerbated during the study. Participants with well-controlled hypertension, diabetes&#xD;
             or hypercholesterolemia are not excluded as long as their medication does not&#xD;
             interfere with the study.&#xD;
&#xD;
          4. Any other clinically significant pulmonary disease except for asthma, including&#xD;
             chronic obstructive pulmonary disease (COPD), interstitial lung disease, cystic&#xD;
             fibrosis, bronchiectasis, chronic bronchitis, emphysema, active pulmonary&#xD;
             tuberculosis, pulmonary carcinoma, pulmonary fibrosis, or pulmonary hypertension. In&#xD;
             addition, obstructive sleep apnea warranting a prescription for continuous or biphasic&#xD;
             positive airway pressure (continuous positive airway pressure [CPAP] or bilevel&#xD;
             positive airway pressure [BiPAP]).&#xD;
&#xD;
          5. Participants who required systemic corticosteroids (for any reason) within the past 4&#xD;
             weeks.&#xD;
&#xD;
          6. Participants with hypersensitivity to any sympathomimetic drug (for example,&#xD;
             formoterol, albuterol/salbutamol, or salmeterol) or any inhaled, intranasal, or&#xD;
             systemic corticosteroid therapy.&#xD;
&#xD;
          7. Participants taking medication(s) (either daily or as needed) with the potential to&#xD;
             affect the course of asthma or to interact with sympathomimetic amines, for example:&#xD;
&#xD;
               1. Oral β-blockers.&#xD;
&#xD;
               2. Strong cytochrome P450 3A4 inhibitors (for example, ritonavir).&#xD;
&#xD;
               3. Monoclonal antibodies/Biologic agents which may affect the course of asthma (such&#xD;
                  as mepolizumab, reslizumab, lebrikizumab, and others).&#xD;
&#xD;
          8. Viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear&#xD;
             infection within 2 weeks prior to Screening or during the Run-in Period.&#xD;
&#xD;
          9. Factors (for example, infirmity, disability or geographic location) that the&#xD;
             Investigator feels would likely limit the participant's compliance with the study&#xD;
             protocol or scheduled clinic visits.&#xD;
&#xD;
         10. Anti-Immunoglobulin E (IgE) (such as omalizumab) use within the 6 months prior to&#xD;
             screening.&#xD;
&#xD;
         11. History of alcohol or drug abuse within the last 6 months.&#xD;
&#xD;
         12. A positive urine drug screen at Screening. Exceptions are made for a positive urine&#xD;
             drug screen at Screening for opiates or stimulants if there is a documented&#xD;
             prescription with supporting medical history and diagnosis, and the Principal&#xD;
             Investigator assesses there are no safety concerns with participant participation.&#xD;
             Screened participants with a urine drug screen positive for&#xD;
             marijuana/tetrahydrocannabinol are not eligible for study participation, without&#xD;
             exceptions. Repeat drug screening is not allowed.&#xD;
&#xD;
         13. Have received any other investigational treatment within 30 days (or within 5 terminal&#xD;
             half-lives of the investigational drug whichever is longer) of Screening or plans to&#xD;
             receive investigational treatment within 30 days after the study is completed.&#xD;
&#xD;
         14. Be an Investigator, employee, or otherwise be directly affiliated with the study site,&#xD;
             Watson Laboratories Inc. and affiliates, or service provider involved in the study&#xD;
             including being an immediate family member of an Investigator or site employee (that&#xD;
             is, spouse, parent, child, or sibling), whether biological or legally adopted or in&#xD;
             foster care.&#xD;
&#xD;
         15. Non-compliance with the study requirements, rules, and procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 100</name>
      <address>
        <city>Surprise</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>111</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>114</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>104</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>103</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>105</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>107</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>106</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>113</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>112</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>108</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>115</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>116</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>110</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>109</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>102</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <results_first_submitted>September 26, 2019</results_first_submitted>
  <results_first_submitted_qc>November 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2019</results_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02495168/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02495168/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants (N=1714) were provided a generic placebo pressurized metered dose inhaler (pMDI) device for use during a 2-week Run-in Period for device training. Then, qualified participants (N=1147) were randomly assigned to treatment on a 4:4:1 ratio of generic budesonide/formoterol fumarate dihydrate, Symbicort, or Placebo, respectively.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Generic Budesonide/Formoterol Fumarate Dihydrate</title>
          <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 microgram [μg]/4.5 μg) pMDI for up to 50 days.</description>
        </group>
        <group group_id="P2">
          <title>Symbicort (Budesonide/Formoterol Fumarate Dihydrate)</title>
          <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="504"/>
                <participants group_id="P2" count="516"/>
                <participants group_id="P3" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="501"/>
                <participants group_id="P2" count="514"/>
                <participants group_id="P3" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent-to-Treat Population</title>
              <participants_list>
                <participants group_id="P1" count="468"/>
                <participants group_id="P2" count="478"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Day1 Per-protocol Set (D1PPS) Population</title>
              <participants_list>
                <participants group_id="P1" count="437"/>
                <participants group_id="P2" count="437"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Day 42 (D42PPS) Population</title>
              <participants_list>
                <participants group_id="P1" count="382"/>
                <participants group_id="P2" count="383"/>
                <participants group_id="P3" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="466"/>
                <participants group_id="P2" count="462"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other than Specified</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not Complete Final Visit On Time</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized participants who received at least 1 dose of study drug during Treatment Period (Safety Population).</population>
      <group_list>
        <group group_id="B1">
          <title>Generic Budesonide/Formoterol Fumarate Dihydrate</title>
          <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
        </group>
        <group group_id="B2">
          <title>Symbicort (Budesonide/Formoterol Fumarate Dihydrate)</title>
          <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="501"/>
            <count group_id="B2" value="514"/>
            <count group_id="B3" value="126"/>
            <count group_id="B4" value="1141"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="501"/>
                    <count group_id="B2" value="514"/>
                    <count group_id="B3" value="126"/>
                    <count group_id="B4" value="1141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" spread="15.39"/>
                    <measurement group_id="B2" value="43.9" spread="15.56"/>
                    <measurement group_id="B3" value="41.5" spread="15.88"/>
                    <measurement group_id="B4" value="43.1" spread="15.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="501"/>
                    <count group_id="B2" value="514"/>
                    <count group_id="B3" value="126"/>
                    <count group_id="B4" value="1141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="292"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="661"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="501"/>
                    <count group_id="B2" value="514"/>
                    <count group_id="B3" value="126"/>
                    <count group_id="B4" value="1141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="399"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="330"/>
                    <measurement group_id="B2" value="334"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="742"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="501"/>
                    <count group_id="B2" value="514"/>
                    <count group_id="B3" value="126"/>
                    <count group_id="B4" value="1141"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="199"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="402"/>
                    <measurement group_id="B2" value="410"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="909"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>FEV1 was measured using spirometry in accordance with the American Thoracic Society/European Respiratory Society (ATS/ERS) consensus guidelines. Data collected at pre-inhalation at Baseline is presented.</description>
          <population>Participants who received at least 1 dose of study drug, no major inclusion/exclusion violations, and enrolled in the study only once (Modified Intent-to-Treat [mITT] Population) and with evaluable FEV1 data.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="466"/>
                    <count group_id="B2" value="476"/>
                    <count group_id="B3" value="111"/>
                    <count group_id="B4" value="1053"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.113" spread="0.5524"/>
                    <measurement group_id="B2" value="2.083" spread="0.5400"/>
                    <measurement group_id="B3" value="2.136" spread="0.5975"/>
                    <measurement group_id="B4" value="2.102" spread="0.5515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Equivalence Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV1 Area Under Curve [AUC0-12]) on the First Day of Treatment</title>
        <description>FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Baseline-adjusted area under the serial FEV1-time curve was calculated from Time 0 to 12 hours on the first day of the Treatment Period (Day 1). FEV1 AUC0-12 was calculated from baseline-adjusted values using the linear trapezoidal method. The calculation assumed that at time of dosing (Time 0) the baseline adjusted FEV1 was also 0. The calculation proceeded over all available post-dose FEV1 assessments on Day 1 (including unscheduled time points, if any) using actual elapsed time from dosing. FEV1 baseline defined as the average of predose FEV1 values obtained on Day 1. If some of these values were missing, the average was calculated using the available values, however, a minimum of 2 predose FEV1 values were required; participants who had only 1 or no predose FEV1 measurements on Day 1 would have their FEV1 baseline missing, and the participant was to be excluded from analysis.</description>
        <time_frame>0 to 12 hours on Day 1</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug, no major inclusion/exclusion violations, enrolled in the study only once, and no major protocol violations that impacted analysis of the Day 1 FEV1 AUC (D1PPS Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Generic Budesonide/Formoterol Fumarate Dihydrate</title>
            <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort (Budesonide/Formoterol Fumarate Dihydrate)</title>
            <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Equivalence Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV1 Area Under Curve [AUC0-12]) on the First Day of Treatment</title>
          <description>FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Baseline-adjusted area under the serial FEV1-time curve was calculated from Time 0 to 12 hours on the first day of the Treatment Period (Day 1). FEV1 AUC0-12 was calculated from baseline-adjusted values using the linear trapezoidal method. The calculation assumed that at time of dosing (Time 0) the baseline adjusted FEV1 was also 0. The calculation proceeded over all available post-dose FEV1 assessments on Day 1 (including unscheduled time points, if any) using actual elapsed time from dosing. FEV1 baseline defined as the average of predose FEV1 values obtained on Day 1. If some of these values were missing, the average was calculated using the available values, however, a minimum of 2 predose FEV1 values were required; participants who had only 1 or no predose FEV1 measurements on Day 1 would have their FEV1 baseline missing, and the participant was to be excluded from analysis.</description>
          <population>Randomized participants who received at least 1 dose of study drug, no major inclusion/exclusion violations, enrolled in the study only once, and no major protocol violations that impacted analysis of the Day 1 FEV1 AUC (D1PPS Population).</population>
          <units>Liter*hour (Lh)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="437"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.637" spread="3.2532"/>
                    <measurement group_id="O2" value="3.584" spread="2.9913"/>
                    <measurement group_id="O3" value="1.460" spread="3.3183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>To show the clinical equivalence, an analysis of covariance (ANCOVA) model was fit on the participants from the generic budesonide/formoterol fumarate and Symbicort groups only, with the endpoint as outcome and treatment, study site and treatment by site interaction as fixed effects and FEV1 baseline value as covariate. If the treatment-by-site interaction factor was not significant at the 0.05 level, the model was to be rerun without the interaction term.</non_inferiority_desc>
            <param_type>Test/Referece LS Mean Ratio</param_type>
            <param_value>101.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.7</ci_lower_limit>
            <ci_upper_limit>111.9</ci_upper_limit>
            <estimate_desc>Fieller's formula was applied to calculate the 90% confidence interval (CI) for the generic budesonide/formoterol fumarate and Symbicort LS mean ratio; covariance between treatment means was assumed to be 0.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Superiority Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV AUC0-12) on the First Day of Treatment</title>
        <description>FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Baseline-adjusted area under the serial FEV1-time curve was calculated from Time 0 to 12 hours on the first day of the Treatment Period (Day 1). FEV1 AUC0-12 was calculated from baseline-adjusted values using the linear trapezoidal method. The calculation assumed that at time of dosing (Time 0) the baseline adjusted FEV1 was also 0. The calculation proceeded over all available post-dose FEV1 assessments on Day 1 (including unscheduled time points, if any) using actual elapsed time from dosing. FEV1 baseline defined as the average of predose FEV1 values obtained on Day 1. If some of these values were missing, the average was calculated using the available values, however, a minimum of 2 predose FEV1 values were required; participants who had only 1 or no predose FEV1 measurements on Day 1 would have their FEV1 baseline missing, and the participant was to be excluded from analysis.</description>
        <time_frame>0 to 12 hours on Day 1</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug, no major inclusion/exclusion violations, and enrolled in the study only once (mITT Population) and with evaluable FEV1 AUC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Generic Budesonide/Formoterol Fumarate Dihydrate</title>
            <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort (Budesonide/Formoterol Fumarate Dihydrate)</title>
            <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Superiority Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV AUC0-12) on the First Day of Treatment</title>
          <description>FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Baseline-adjusted area under the serial FEV1-time curve was calculated from Time 0 to 12 hours on the first day of the Treatment Period (Day 1). FEV1 AUC0-12 was calculated from baseline-adjusted values using the linear trapezoidal method. The calculation assumed that at time of dosing (Time 0) the baseline adjusted FEV1 was also 0. The calculation proceeded over all available post-dose FEV1 assessments on Day 1 (including unscheduled time points, if any) using actual elapsed time from dosing. FEV1 baseline defined as the average of predose FEV1 values obtained on Day 1. If some of these values were missing, the average was calculated using the available values, however, a minimum of 2 predose FEV1 values were required; participants who had only 1 or no predose FEV1 measurements on Day 1 would have their FEV1 baseline missing, and the participant was to be excluded from analysis.</description>
          <population>Randomized participants who received at least 1 dose of study drug, no major inclusion/exclusion violations, and enrolled in the study only once (mITT Population) and with evaluable FEV1 AUC data.</population>
          <units>Lh</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="478"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.630" spread="3.2528"/>
                    <measurement group_id="O2" value="3.573" spread="2.9960"/>
                    <measurement group_id="O3" value="1.449" spread="3.3033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LS means difference and p-value from ANCOVA model with treatment and site as fixed effects, baseline FEV1 as covariate and endpoint as outcome on generic budesonide/formoterol fumarate dihydrate and Placebo participants only.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.334</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.673</ci_lower_limit>
            <ci_upper_limit>2.996</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LS means difference and p-value from ANCOVA model with treatment and site as fixed effects, baseline FEV1 as covariate and endpoint as outcome on Symbicort and Placebo participants only.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.606</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.939</ci_lower_limit>
            <ci_upper_limit>3.273</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Equivalence Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment</title>
        <description>FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42. If a participant had no predose assessment on Day 42, the average of all available predose assessments on the last day (for example, Early Termination visit [up to Day 50]) when at least 1 predose FEV1 assessments was available was imputed, if the participant discontinued due to lack of efficacy, otherwise there was no imputation. Baseline was defined as the average of at least 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: [FEV1 at end of treatment] - [Baseline FEV1].</description>
        <time_frame>Day 1 up to Day 50</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug, no major inclusion/exclusion violations, enrolled in the study only once, and no major protocol violations that impacted analysis of the Day 42 FEV1 AUC (D42PPS Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Generic Budesonide/Formoterol Fumarate Dihydrate</title>
            <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort (Budesonide/Formoterol Fumarate Dihydrate)</title>
            <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Equivalence Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment</title>
          <description>FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42. If a participant had no predose assessment on Day 42, the average of all available predose assessments on the last day (for example, Early Termination visit [up to Day 50]) when at least 1 predose FEV1 assessments was available was imputed, if the participant discontinued due to lack of efficacy, otherwise there was no imputation. Baseline was defined as the average of at least 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: [FEV1 at end of treatment] - [Baseline FEV1].</description>
          <population>Randomized participants who received at least 1 dose of study drug, no major inclusion/exclusion violations, enrolled in the study only once, and no major protocol violations that impacted analysis of the Day 42 FEV1 AUC (D42PPS Population).</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="383"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.278" spread="0.3306"/>
                    <measurement group_id="O2" value="0.283" spread="0.3241"/>
                    <measurement group_id="O3" value="0.094" spread="0.3298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>To show the clinical equivalence, an ANCOVA model was fit on the participants from the generic budesonide/formoterol fumarate and Symbicort groups only, with the endpoint as outcome and treatment, study site and treatment-by site interaction as fixed effects and FEV1 baseline value as covariate. If the treatment-by-site interaction factor was not significant at the 0.05 level, the model was to be rerun without the interaction term.</non_inferiority_desc>
            <param_type>Test/Reference LS Mean Ratio</param_type>
            <param_value>99.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.0</ci_lower_limit>
            <ci_upper_limit>114.5</ci_upper_limit>
            <estimate_desc>Fieller's formula was applied to calculate the 90% CI for the generic budesonide/formoterol fumarate and Symbicort LS mean ratio; covariance between treatment means was assumed to be 0.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Superiority Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment</title>
        <description>FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42. If a participant had no predose assessment on Day 42, the average of all available predose assessments on the last day (for example, Early Termination visit [up to Day 50]) when at least 1 predose FEV1 assessments was available was imputed, if the participant discontinued due to lack of efficacy, otherwise there was no imputation. Baseline was defined as the average of at least 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: [FEV1 at end of treatment] - [Baseline FEV1].</description>
        <time_frame>Day 1 up to Day 50</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug, no major inclusion/exclusion violations, and enrolled in the study only once (mITT Population) and with evaluable baseline-adjusted average predose FEV1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Generic Budesonide/Formoterol Fumarate Dihydrate</title>
            <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
          </group>
          <group group_id="O2">
            <title>Symbicort (Budesonide/Formoterol Fumarate Dihydrate)</title>
            <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Superiority Analysis of Baseline-Adjusted Average Predose FEV1 at End of Treatment</title>
          <description>FEV1 was measured using spirometry in accordance with the ATS/ERS consensus guidelines. Average predose FEV1 at End of Treatment defined as the average of all predose assessments on Day 42. If a participant had no predose assessment on Day 42, the average of all available predose assessments on the last day (for example, Early Termination visit [up to Day 50]) when at least 1 predose FEV1 assessments was available was imputed, if the participant discontinued due to lack of efficacy, otherwise there was no imputation. Baseline was defined as the average of at least 2 predose FEV1 values obtained on Day 1. The endpoint of baseline-adjusted predose FEV1 at end of treatment was calculated as follows: [FEV1 at end of treatment] - [Baseline FEV1].</description>
          <population>Randomized participants who received at least 1 dose of study drug, no major inclusion/exclusion violations, and enrolled in the study only once (mITT Population) and with evaluable baseline-adjusted average predose FEV1 data.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="478"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.269" spread="0.3238"/>
                    <measurement group_id="O2" value="0.277" spread="0.3156"/>
                    <measurement group_id="O3" value="0.124" spread="0.3673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LS means difference and p-value from ANCOVA model with treatment and site as fixed effects, baseline FEV1 as covariate and endpoint as outcome on generic budesonide/formoterol fumarate dihydrate and Placebo participants only.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.159</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.093</ci_lower_limit>
            <ci_upper_limit>0.226</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LS means difference and p-value from ANCOVA model with treatment and site as fixed effects, baseline FEV1 as covariate and endpoint as outcome on Symbicort and Placebo participants only.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.164</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.099</ci_lower_limit>
            <ci_upper_limit>0.229</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First day of the Treatment Period (Day 1) up to Day 72</time_frame>
      <desc>Randomized participants who received at least 1 dose of study drug during Treatment Period (Safety Population).</desc>
      <group_list>
        <group group_id="E1">
          <title>Generic Budesonide/Formoterol Fumarate Dihydrate</title>
          <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
        </group>
        <group group_id="E2">
          <title>Symbicort (Budesonide/Formoterol Fumarate Dihydrate)</title>
          <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants administered 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <description>This is a sex-specific adverse event that only affects female participants.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Hernia pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <description>This is a sex-specific adverse event that only affects female participants.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Antinuclear antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Glucose urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bunion operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="514"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, CE Studies</name_or_title>
      <organization>Teva Pharmaceuticals Inc. USA</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedInfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

